JP2021525530A5 - - Google Patents
Info
- Publication number
- JP2021525530A5 JP2021525530A5 JP2020567078A JP2020567078A JP2021525530A5 JP 2021525530 A5 JP2021525530 A5 JP 2021525530A5 JP 2020567078 A JP2020567078 A JP 2020567078A JP 2020567078 A JP2020567078 A JP 2020567078A JP 2021525530 A5 JP2021525530 A5 JP 2021525530A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- ggggs
- antigen
- recognition domain
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679597P | 2018-06-01 | 2018-06-01 | |
| US62/679,597 | 2018-06-01 | ||
| PCT/US2019/034981 WO2019232425A1 (en) | 2018-06-01 | 2019-05-31 | Suppression of cytokine release syndrome in chimeric antigen receptor cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021525530A JP2021525530A (ja) | 2021-09-27 |
| JP2021525530A5 true JP2021525530A5 (enExample) | 2022-06-30 |
Family
ID=68696762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567078A Pending JP2021525530A (ja) | 2018-06-01 | 2019-05-31 | キメラ抗原受容体細胞治療薬を用いたサイトカイン放出症候群の抑制 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20200054675A1 (enExample) |
| EP (1) | EP3802578A4 (enExample) |
| JP (1) | JP2021525530A (enExample) |
| CN (1) | CN112533942A (enExample) |
| WO (1) | WO2019232425A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12350349B2 (en) | 2016-08-03 | 2025-07-08 | Washington University | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors |
| WO2019032628A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS |
| US20200040056A1 (en) * | 2018-05-31 | 2020-02-06 | Washington University | Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies |
| IL279063B2 (en) * | 2018-05-31 | 2026-05-01 | Washington University St Louis | Chimeric antigen receptor T cells for cancer treatment |
| CN112533942A (zh) | 2018-06-01 | 2021-03-19 | 华盛顿大学 | 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制 |
| CN109735558B (zh) * | 2018-12-12 | 2022-04-15 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
| IL285941B1 (en) | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN |
| BR112022003553A2 (pt) | 2019-08-30 | 2022-05-24 | Allogene Therapeutics Inc | Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta |
| EP4076476A4 (en) * | 2019-12-17 | 2023-11-22 | The General Hospital Corporation | MODIFIED IMMUNE CELLS WITH REDUCED TOXICITY AND THEIR USES |
| EP3845646A1 (en) | 2019-12-30 | 2021-07-07 | Secarna Pharmaceuticals GmbH & Co. KG | Modified antisense oligonucleotide for inhibition of foxp3 expression |
| PE20221757A1 (es) * | 2020-02-24 | 2022-11-11 | Allogene Therapeutics Inc | Celulas t con car de bcma con actividades mejoradas |
| US20230149465A1 (en) * | 2020-04-06 | 2023-05-18 | Celledit Llc | Genetically modified immune cells expressing a chimeric antigen receptor and having reduced proinflammatory cytokine signaling |
| CN111548420B (zh) * | 2020-05-14 | 2021-10-15 | 深圳普瑞金生物药业有限公司 | 一种抗间皮素嵌合抗原受体、表达基因、表达载体、t细胞及其用途 |
| WO2022098756A1 (en) * | 2020-11-03 | 2022-05-12 | WUGEN, Inc. | Chimeric antigen receptor cell therapy |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| CA3207206A1 (en) * | 2021-02-01 | 2022-08-04 | Lingfeng LIU | Targeted protein degradation system and use thereof |
| CN112876535B (zh) * | 2021-02-08 | 2023-06-30 | 浙江华缔药业集团医药开发有限公司 | 生物活性多肽及其应用 |
| US11804212B2 (en) * | 2021-04-23 | 2023-10-31 | Google Llc | Streaming automatic speech recognition with non-streaming model distillation |
| IL310118A (en) * | 2021-07-16 | 2024-03-01 | Orthobio Therapeutics Inc | Gene editing to improve joint function |
| EP4394043A4 (en) * | 2021-08-24 | 2025-09-03 | Cells & Genes Biotech Shanghai Co Ltd | CELL MODIFICATION METHOD |
| CN114410686B (zh) * | 2021-12-24 | 2023-10-03 | 武汉大学 | 一种工程化外泌体原位纳米疫苗及其制备方法和应用 |
| EP4504221A4 (en) * | 2022-03-22 | 2026-02-25 | Celyntra Therapeutics Sa | Compositions and methods for generating cells with reduced immunogenicity |
| WO2023225249A1 (en) * | 2022-05-20 | 2023-11-23 | President And Fellows Of Harvard College | Methods and compositions relating to treatment of cns diseases |
| CN116102662A (zh) * | 2022-10-10 | 2023-05-12 | 武汉波睿达生物科技有限公司 | 一种靶向ca9的融合嵌合抗原受体、重组表达载体及其应用 |
| WO2024084520A1 (en) * | 2022-10-20 | 2024-04-25 | Microcrispr Pvt Ltd. | Attenuation of cytokine release syndrome in immunotherapy |
| EP4604966A1 (en) * | 2022-10-20 | 2025-08-27 | Microcrispr Pvt Ltd. | Attenuation of cytokine release syndrome in immunotherapy |
| WO2024084518A1 (en) * | 2022-10-20 | 2024-04-25 | Microcrispr Pvt Ltd. | Attenuation of cytokine release syndrome in immunotherapy |
| CN116240173B (zh) * | 2023-02-02 | 2024-09-27 | 西安电子科技大学 | 一种冷热肿瘤调控型car-单核/巨噬细胞及其制备方法和应用 |
| CN116199781B (zh) * | 2023-02-22 | 2025-07-18 | 成都优赛诺生物科技有限公司 | 一种靶向cd22的单域抗体、嵌合抗原受体及其应用 |
| CN116754774B (zh) * | 2023-05-12 | 2026-03-06 | 浙江大学医学院附属第一医院 | 一种细胞因子组合物及应用 |
| WO2025077790A1 (en) * | 2023-10-11 | 2025-04-17 | Chengdu Ucello Biotechnology Co., Limited | Engineered immune cells and uses thereof |
| CN117186202B (zh) * | 2023-11-08 | 2024-02-02 | 北京大学第三医院（北京大学第三临床医学院） | 一种新细胞因子csbf及其在干眼治疗中的应用 |
| CN117866110B (zh) * | 2023-12-27 | 2024-06-11 | 广东唯泰生物科技有限公司 | 一种靶向flt-3的第四代嵌合抗原受体及其应用 |
| CN117757751A (zh) * | 2023-12-29 | 2024-03-26 | 恩替(苏州)生物科技有限公司 | 共表达pd-1-il-7r嵌合受体的嵌合抗原受体t细胞及其用途 |
| WO2026085500A1 (en) * | 2024-10-17 | 2026-04-23 | Orthobio Therapeutics, Inc. | Transmembrane receptor gene editing |
| CN119345372A (zh) * | 2024-10-28 | 2025-01-24 | 北京大学人民医院 | Cd132在治疗aml中的应用 |
| WO2026117685A1 (en) * | 2024-11-27 | 2026-06-04 | Cytoagents, Inc. | Chimeric antigen receptor (car) t-cell adjuvant therapies |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4019041T3 (pl) | 2012-07-13 | 2023-05-08 | The Trustees Of The University Of Pennsylvania | Kontrola toksyczności wobec aktywności przeciwnowotworowej CAR |
| WO2015066262A1 (en) * | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
| NZ759969A (en) | 2013-12-20 | 2022-12-23 | Fred Hutchinson Cancer Center | Tagged chimeric effector molecules and receptors thereof |
| EP3243831A1 (en) * | 2014-02-27 | 2017-11-15 | Ucl Business Plc | Variants of the proliferation-inducing ligand (april) |
| HRP20220890T1 (hr) * | 2015-02-06 | 2022-10-14 | National University Of Singapore | Postupci za povećanje učinkovitosti terapijskih imunosnih stanica |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US20180371052A1 (en) | 2015-12-22 | 2018-12-27 | Icell Gene Therapeutics Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| US11111505B2 (en) * | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| KR102614675B1 (ko) * | 2016-04-15 | 2023-12-19 | 메모리얼 슬로안 케터링 캔서 센터 | 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법 |
| US12350349B2 (en) | 2016-08-03 | 2025-07-08 | Washington University | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors |
| WO2018064602A1 (en) * | 2016-09-30 | 2018-04-05 | Baylor College Of Medicine | Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease |
| CN106636090B (zh) * | 2016-10-11 | 2019-08-09 | 上海优卡迪生物医药科技有限公司 | 人源白细胞介素6的siRNA、重组表达CAR-T载体及其构建方法和应用 |
| WO2018073393A2 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| WO2018073391A1 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| EP3568406A4 (en) * | 2017-01-10 | 2020-10-21 | The General Hospital Corporation | T LYMPHOCYTES EXPRESSING A CHEMERICAL ANTIGENIC RECEPTOR |
| CN111757744A (zh) * | 2017-10-02 | 2020-10-09 | 人源股份有限公司 | 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法 |
| JP7621795B2 (ja) | 2017-10-19 | 2025-01-27 | セレクティス | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
| CA3082611A1 (en) | 2017-11-17 | 2019-05-23 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for alleviating cytokine release syndrome |
| CN112533942A (zh) | 2018-06-01 | 2021-03-19 | 华盛顿大学 | 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制 |
-
2019
- 2019-05-31 CN CN201980044894.5A patent/CN112533942A/zh active Pending
- 2019-05-31 US US16/428,362 patent/US20200054675A1/en not_active Abandoned
- 2019-05-31 EP EP19810633.8A patent/EP3802578A4/en not_active Withdrawn
- 2019-05-31 WO PCT/US2019/034981 patent/WO2019232425A1/en not_active Ceased
- 2019-05-31 JP JP2020567078A patent/JP2021525530A/ja active Pending
-
2022
- 2022-05-17 US US17/746,645 patent/US12304941B2/en active Active
-
2025
- 2025-03-19 US US19/084,433 patent/US20260022156A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7140861B2 (ja) | ヘテロ二量体多重特異性抗体フォーマット | |
| JP2023518134A5 (enExample) | ||
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| JP2024083331A5 (enExample) | ||
| JP2025109759A5 (enExample) | ||
| IL275743A (en) | New bispecific format suitable for use in high-through-put screening | |
| JP2021525518A5 (enExample) | ||
| JP2018172439A5 (enExample) | ||
| US20170073415A1 (en) | Novel multispecific molecules and novel treatment methods based on such multispecific molecules | |
| IL276903B1 (en) | Bispecific egfr/cd16 antigen-binding protein | |
| IL299221A (en) | Cd3 binding antibodies | |
| JP2021515798A5 (enExample) | ||
| JP2017504578A5 (enExample) | ||
| RU2016138347A (ru) | Трифункциональная антигенсвязывающая молекула | |
| WO2002002781A1 (en) | Heterodimeric fusion proteins | |
| JP2017522891A5 (enExample) | ||
| JP2016536322A5 (enExample) | ||
| JP2023519106A5 (enExample) | ||
| JP2022545647A5 (enExample) | ||
| JP2020522267A (ja) | 少なくともｃｄ３及びｈｓａを標的とするヘテロ二量体多重特異性抗体フォーマット | |
| TWI690539B (zh) | 一個需依賴標靶細胞使T細胞接合及活化之不對稱異二聚Fc-ScFv融合抗體形式及其在癌症治療上之應用 | |
| JP2022009816A5 (enExample) | ||
| JP2024507540A5 (enExample) | ||
| JP2020516603A5 (enExample) | ||
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение |